EUVIMEDEUVIMED entdecken
Crossref

Clinical Heterogeneity of TNFRSF13B Variants: A Monogenic Cause or a Genetic Modifier?

Begum Cicek iD, Deniz Ilgun Gurel iD, Ismail Yaz iD, Sevda Tuten Dal iD, Hacer Neslihan Bildik iD, Baran Erman iD, Canberk Ipsir iD, Elif Soyak Aytekin iD, Saliha Esenboga iD, Ilhan Tezcan, Deniz Cagdas iD

Immunology · 2026-12 · 179 (4) · 609-623

DOI: 10.1111/imm.70192 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, online erschienen am 14.08.2026. Verfasst von Begum Cicek und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology, Department of Pediatric Basic Sciences, Institute of Child Health, Hacettepe University, Ankara, Turkey. Hauptthemen laut MEDLINE: Transmembrane Activator and CAML Interactor Protein, Common Variable Immunodeficiency, Mutation, B-Lymphocytes. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Scientific and Technological Research Council of Turkey, Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transmembrane activator and calcium‐modulator and cyclophilin‐ligand interactor (TACI), encoded by TNFRSF13B, plays a central role in B cell maturation and antibody responses through its interactions with BAFF and APRIL, with variants being linked to common variable immunodeficiency (CVID) and selective IgA deficiency. To characterise the clinical, immunological and genetic spectrum of these individuals, we recruited 30 participants (21 patients and nine family members) and classified patients into Group 1 ( n = 16), carrying only TACI variants and Group 2 ( n = 5), carrying both an IEI‐related variant and an additional TACI variant. With a male/female ratio of 12/9, the median age was 2 years at symptom onset and 14 years at genetic diagnosis. Common clinical manifestations included recurrent infections (90%), autoimmune/inflammatory features (62%) and lymphoproliferation (57%). Twelve distinct TNFRSF13B mutations were identified, predominantly clustering in the cysteine‐rich domain 2 (CRD2), with Cys104Arg being the most frequent (57%) variant. Immunophenotyping revealed decreased switched‐memory and marginal zone B cells, reduced naïve CD4 + T cells and increased effector memory subsets. Notably, clinical and laboratory features overlapped between Groups 1 and 2, as well as between monoallelic and biallelic TNFRSF13B variant carriers. Patients with TNFRSF13B variants display broad phenotypic heterogeneity ranging from asymptomatic carriage to CVID and combined immunodeficiency phenotypes. Given the high polymorphism ratio and incomplete penetrance observed, TACI acts as both a genetic modifier and a monogenic disease‐causing gene in this cohort, suggesting that coexisting genetic variants and exposomal factors likely determine the clinical expression and disease severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transmembrane Activator and CAML Interactor ProteinCommon Variable ImmunodeficiencyMutationB-LymphocytesHumansFemaleMaleChildChild, PreschoolAdolescentGenetic Predisposition to DiseasePhenotypeAdultYoung AdultImmunophenotypingInfant

Stichwörter der Autor:innen

NGSTACIautoimmunitycommon variable immunodeficiencymodifier gene

Substanzen

Transmembrane Activator and CAML Interactor ProteinTNFRSF13B protein, human

Autor:innen und Institutionen

  • Division of Immunology, Department of Pediatric Basic Sciences, Institute of Child Health, Hacettepe University, Ankara, Turkey.
  • Ihsan Dogramaci Children's Hospital, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Pediatric Immunology Laboratory, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
  • Division of Immunology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
  • Can Sucak Research Laboratory for Translational Immunology, Hacettepe University, Ankara, Turkey.

ORCID-Profile: Begum Cicek, Deniz Ilgun Gurel, Ismail Yaz, Sevda Tuten Dal, Hacer Neslihan Bildik, Baran Erman, Canberk Ipsir, Elif Soyak Aytekin, Saliha Esenboga, Deniz Cagdas

Förderung

  • Scientific and Technological Research Council of Turkey
  • Türkiye Bilimsel ve Teknolojik Araştırma Kurumu

Zitieren

APA

Cicek, B., Gurel, D. I., Yaz, I., Dal, S. T., Bildik, H. N., Erman, B., Ipsir, C., Aytekin, E. S., Esenboga, S., Tezcan, I., & Cagdas, D. (2026). Clinical Heterogeneity of TNFRSF13B Variants: A Monogenic Cause or a Genetic Modifier?. Immunology, 179(4), 609-623. https://doi.org/10.1111/imm.70192

Vancouver

Cicek B, Gurel DI, Yaz I, Dal ST, Bildik HN, Erman B, et al. Clinical Heterogeneity of TNFRSF13B Variants: A Monogenic Cause or a Genetic Modifier?. Immunology. 2026;179(4):609-623. doi:10.1111/imm.70192

BibTeX
@article{Cicek2026,
  author = {Cicek, Begum and Gurel, Deniz Ilgun and Yaz, Ismail and Dal, Sevda Tuten and Bildik, Hacer Neslihan and Erman, Baran and Ipsir, Canberk and Aytekin, Elif Soyak and Esenboga, Saliha and Tezcan, Ilhan and Cagdas, Deniz},
  title = {Clinical Heterogeneity of TNFRSF13B Variants: A Monogenic Cause or a Genetic Modifier?},
  journal = {Immunology},
  year = {2026},
  volume = {179},
  number = {4},
  pages = {609--623},
  doi = {10.1111/imm.70192}
}
Kostenlos starten →